Equibles does not estimate personal net worth.
Get an email with a short summary when Rigel Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get RIGL alertsDean Schorno is recorded as CFO at Rigel Pharmaceuticals Inc (RIGL). The newest filing on record that lists Dean Schorno as CFO at Rigel Pharmaceuticals Inc (RIGL) is dated April 3, 2026. The proxy statement of Rigel Pharmaceuticals Inc reports total compensation of $1,377,793 for Dean Schorno in fiscal 2024, including a base salary of $495,100. Disclosed compensation is on record for 7 fiscal years. Dean Schorno has spoken on 27 earnings calls across 1 company, most recently for Rigel Pharmaceuticals Inc on November 5, 2026. Rigel Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rigel Pharmaceuticals Inc includes Raul R. Rodriguez (CEO and Board Member), Raul Rodriguez (CEO and Board Member), Raymond Furey (General Counsel) and 7 others.
“Among slide 30, we reported net product sales of $72.3 million for the third quarter, a growth of 13% year-over-year, including Tavo East net product sales of $46 million, an increase of 3% year-over-year, Amretto net product sales of $9.8 million, a decrease of 11% year-over-year, Resoliti net product sales of $9.9…”
“We reported net product sales of $67 million for the second quarter, a growth of 14% year-over-year, including Tavoli's net product sales of $47.4 million, a growth of 18% year-over-year.”
“We reported net product sales of $54.9 million for the first quarter, a growth of 26% year-over-year, including Tabilis net product sales of $37.3 million, a growth of 31% year-over-year, Gabretto net product sales of $9.6 million, a growth of 7% year-over-year.”
“I'm on slide number 29, we reported net product sales of $65.4 million for the fourth quarter, a growth of 41% year-over-year, including Tavoli's net product sales of $45.6 million, a growth of 47% year-over-year, Debreto net product sales of $10.2 million, a growth of 27% year-over-year.”
“I'd like to provide a brief update on our collaboration with Lilly. Ocadusertib, the non-CNS penetrant RIPK1 inhibitor, previously referred to as R552, is currently being studied in an adaptive Phase IIa/IIb clinical trial in up to 380 patients with active moderate to severe rheumatoid arthritis.”
Start not stated–present
Last confirmed April 3, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | $495,100 | $1,377,793 |
| 2023 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | $476,100 | $1,210,005 |
| 2022 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | $460,000 | $1,139,450 |
| 2020 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | $424,360 | $1,202,524 |
| 2019 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | $412,000 | $1,033,216 |
| 2018 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | $237,808 | $1,194,161 |
| 2017 | Rigel Pharmaceuticals Inc (RIGL) | Executive Vice President and Chief Financial Officer | — | — |
